Study of Busulfan for Refractory Central Nervous System (CNS) Tumors

NCT00836628 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped slow accrual

Conditions

Refractory Brain Tumors

Interventions

DRUG: Busulfan

Sponsor

Ann & Robert H Lurie Children's Hospital of Chicago